St. James Investment Advisors LLC Acquires 349 Shares of Johnson & Johnson (NYSE:JNJ)

Posted by Defense World Staff on May 15th, 2023

St. James Investment Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ – Get Rating) by 5.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,614 shares of the company’s stock after purchasing an additional 349 shares during the period. Johnson & Johnson comprises about 2.1% of St. James Investment Advisors LLC’s investment portfolio, making the stock its 12th biggest position. St. James Investment Advisors LLC’s holdings in Johnson & Johnson were worth $1,168,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also added to or reduced their stakes in JNJ. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.2% in the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock valued at $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. State Street Corp lifted its position in Johnson & Johnson by 0.6% during the 3rd quarter. State Street Corp now owns 141,886,311 shares of the company’s stock worth $23,178,548,000 after buying an additional 803,013 shares in the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Johnson & Johnson by 3.3% during the 3rd quarter. Price T Rowe Associates Inc. MD now owns 25,428,626 shares of the company’s stock worth $4,154,022,000 after acquiring an additional 805,831 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Johnson & Johnson by 1.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 17,189,229 shares of the company’s stock worth $3,046,449,000 after purchasing an additional 328,297 shares in the last quarter. Finally, California Public Employees Retirement System grew its stake in shares of Johnson & Johnson by 2.7% during the third quarter. California Public Employees Retirement System now owns 11,751,504 shares of the company’s stock valued at $1,919,726,000 after purchasing an additional 310,473 shares during the last quarter. 67.94% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Trading Down 0.1 %

JNJ opened at $160.78 on Monday. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $417.82 billion, a P/E ratio of 33.64, a P/E/G ratio of 2.77 and a beta of 0.53. The firm’s fifty day simple moving average is $159.10 and its 200 day simple moving average is $166.69. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $183.35.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, April 18th. The company reported $2.68 EPS for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to analysts’ expectations of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.67 earnings per share. As a group, research analysts anticipate that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be given a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a dividend yield of 2.96%. Johnson & Johnson’s payout ratio is 99.58%.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which is available through this link. 0.20% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on JNJ shares. UBS Group initiated coverage on Johnson & Johnson in a report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 price objective on the stock. Raymond James lowered their price objective on Johnson & Johnson from $185.00 to $181.00 and set an “outperform” rating for the company in a research report on Wednesday, April 19th. StockNews.com started coverage on shares of Johnson & Johnson in a research note on Thursday, March 16th. They issued a “strong-buy” rating on the stock. Piper Sandler cut their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Finally, SVB Leerink lowered their target price on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a report on Friday, January 20th. Seven analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.